• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2型疫苗与皮肤

SARS-CoV-2 Vaccines and the Skin.

作者信息

Galván-Casas C, Català A, Muñoz-Santos C

机构信息

Servicio de Dermatología, Hospital Universitario de Móstoles, Móstoles, Madrid, Spain.

Servicio de Dermatología, Sede Plató, Hospital Clínic, Barcelona, Spain.

出版信息

Actas Dermosifiliogr. 2021 Oct;112(9):828-836. doi: 10.1016/j.adengl.2021.07.028. Epub 2021 Aug 28.

DOI:10.1016/j.adengl.2021.07.028
PMID:34483343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8401210/
Abstract

Vaccines against the severe acute respiratory coronavirus 2, which are the first to be used in humans against any coronavirus, were developed and produced in record time. Dermatologic adverse effects appeared during clinical trials and have also been described in the population since approval. Just as descriptions and categorization of skin manifestations of the coronavirus disease 2019 proved important for understanding the disease itself, characterizing the effects of vaccines may also further that goal. This paper reviews the properties of the different types of vaccines currently available and under development and describes how they interact with the immune system and the clinical signs they may cause. We focus on dermatologic adverse effects reported to date and recommendations for managing them.

摘要

针对严重急性呼吸综合征冠状病毒2的疫苗是首批用于人类对抗任何冠状病毒的疫苗，其研发和生产速度创纪录。在临床试验期间出现了皮肤不良反应，自获批以来在人群中也有相关描述。正如对2019冠状病毒病皮肤表现的描述和分类对理解该疾病本身很重要一样，对疫苗效果进行特征描述也可能有助于实现这一目标。本文综述了目前可用和正在研发的不同类型疫苗的特性，并描述了它们如何与免疫系统相互作用以及可能引起的临床症状。我们重点关注迄今为止报告的皮肤不良反应及其管理建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/cea97a9fca0f/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/9a8067924a6c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/6099479a2994/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/df0990782e5c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/8d6d5a4eefb3/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/cea97a9fca0f/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/9a8067924a6c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/6099479a2994/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/df0990782e5c/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/8d6d5a4eefb3/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa88/8401210/cea97a9fca0f/gr5_lrg.jpg

相似文献

1
SARS-CoV-2 Vaccines and the Skin.严重急性呼吸综合征冠状病毒2型疫苗与皮肤
Actas Dermosifiliogr. 2021 Oct;112(9):828-836. doi: 10.1016/j.adengl.2021.07.028. Epub 2021 Aug 28.
2
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
3
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
4
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
5
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
6
Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).关于开发严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗的观点。
Hum Vaccin Immunother. 2020 Oct 2;16(10):2366-2369. doi: 10.1080/21645515.2020.1787064. Epub 2020 Sep 22.
7
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
8
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.预防 SARS-CoV-2 感染和治疗 COVID-19 早期阶段的药理学策略。
Int J Infect Dis. 2021 Mar;104:441-451. doi: 10.1016/j.ijid.2021.01.035. Epub 2021 Jan 18.
9
On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.对严重急性呼吸综合征冠状病毒 2 疫苗的期望设定。
Clin Infect Dis. 2021 Feb 1;72(3):513-514. doi: 10.1093/cid/ciaa726.
10
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.

引用本文的文献

1
Lichenoid Drug Reaction Post-COVID Vaccination with the Modified Chimpanzee Adenovirus.接种改良型黑猩猩腺病毒 COVID 疫苗后的苔藓样药物反应
Indian J Dermatol. 2022 Jul-Aug;67(4):427-428. doi: 10.4103/ijd.ijd_747_21.
2
Spectrum of Mucocutaneous Reactions to COVID-19 Vaccination: A Report from a Web-Based Study from India.新型冠状病毒肺炎疫苗接种的皮肤黏膜反应谱：来自印度一项基于网络研究的报告
Indian J Dermatol. 2022 Mar-Apr;67(2):115-120. doi: 10.4103/ijd.ijd_893_21.

本文引用的文献

1
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.接种 SARS-CoV-2 疫苗后的皮肤反应：一项对 405 例病例的西班牙全国性横断面研究。
Br J Dermatol. 2022 Jan;186(1):142-152. doi: 10.1111/bjd.20639. Epub 2021 Sep 21.
2
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.报告的 Moderna 和辉瑞 COVID-19 疫苗接种后皮肤反应：基于登记的 414 例病例研究。
J Am Acad Dermatol. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Epub 2021 Apr 7.
3
Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series.
辉瑞-生物科技公司新冠疫苗接种后的短暂皮肤表现：一项意大利单中心病例系列研究
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e483-e485. doi: 10.1111/jdv.17268. Epub 2021 Apr 24.
4
Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.医疗工作者中BNT162b2 mRNA新冠疫苗的皮肤表现。“新冠疫苗接种臂”：临床和组织学特征
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e425-e427. doi: 10.1111/jdv.17250. Epub 2021 Apr 19.
5
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.接种第一剂辉瑞-生物科技公司新冠疫苗后出现持续性斑丘疹皮疹。
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e423-e425. doi: 10.1111/jdv.17248. Epub 2021 Apr 8.
6
Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.聚乙二醇和聚山梨酯皮肤试验在评估2019冠状病毒病疫苗反应中的应用：早期报告
Ann Allergy Asthma Immunol. 2021 Jun;126(6):735-738. doi: 10.1016/j.anai.2021.03.012. Epub 2021 Mar 26.
7
May 2021: Heterogeneity in reported skin manifestations of COVID-19 and vaccines.2021年5月：新冠病毒病（COVID-19）及疫苗报告的皮肤表现的异质性
J Am Acad Dermatol. 2021 May;84(5):1251. doi: 10.1016/j.jaad.2021.03.022. Epub 2021 Mar 26.
8
COVID-19 "second wave" and vaccines: the dermatologists' perspective.新冠疫情“第二波”与疫苗：皮肤科医生的观点
Int J Dermatol. 2021 Jul;60(7):889-890. doi: 10.1111/ijd.15547. Epub 2021 Mar 25.
9
Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.过敏性皮肤病患者接种新型冠状病毒肺炎疫苗后发生严重过敏反应的风险——实用建议。欧洲皮肤科和性病学会与外部专家的立场声明
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e362-e365. doi: 10.1111/jdv.17237. Epub 2021 Apr 3.
10
"COVID arm": A reaction to the Moderna vaccine.“新冠手臂”：对莫德纳疫苗的一种反应。
JAAD Case Rep. 2021 Apr;10:92-95. doi: 10.1016/j.jdcr.2021.02.014. Epub 2021 Feb 25.